论文部分内容阅读
化疗肿瘤治疗的常规手段之一,但由于细胞毒药物没有明显的靶向性,导致其副作用十分显著。因此免疫偶联药物由于其良好的靶向性及抗癌活性就成为了研究的热点。文章综述了细胞毒药物与单克隆抗体偶联的各种常用方法,包括使用偶联剂进行偶联、利用肽链进行偶联、利用二硫键进行偶联和利用大分子技术进行偶联,以及抗体偶联药物的研究现状。抗体偶联药物有细胞毒药物、抗体和偶联剂组成,利用各种偶联手段将单克隆抗体与细胞毒药物偶联,不仅可以将细胞毒药物特异性地靶向于肿瘤细胞,而且可以降低细胞毒药物对于正常细胞的杀伤,同时还可以具备缓释、提高药物抗肿瘤活性等效果,是未来肿瘤靶向治疗的发展方向之一。同时文章还结合作者的自身工作,对抗体偶联药物的未来发展方向提出了建议。
Chemotherapy is one of the conventional means of cancer treatment, but due to the lack of obvious targeting of cytotoxic drugs, leading to its side effects is very significant. Therefore, immunoconjugated drugs have become the focus of research because of their good targeting and anti-cancer activity. The article reviews various common methods for conjugating cytotoxic drugs to monoclonal antibodies, including conjugation with coupling agents, coupling with peptide chains, coupling with disulfide bonds and coupling with macromolecular techniques, As well as the research status of antibody conjugated drugs. Antibody-conjugated drugs are composed of cytotoxic drugs, antibodies, and coupling agents. Coupling monoclonal antibodies to cytotoxic drugs using a variety of conjugation methods not only targets cytotoxic drugs specifically to tumor cells, but also allows Reduce cytotoxic drugs for normal cell killing, but also can have sustained-release, improve the anti-tumor activity of drugs and other effects, is the future development of targeted therapy of cancer. At the same time, the article also combined with the author’s own work, made recommendations for the future development of antibody-conjugated drugs.